The US Food and Drug Administration is inching closer to approving Contrave, the first new diet pill in a decade. This is after the experimental obesity drug manufactured by Orexigen Therapeutics got a favourable vote on its risk profile. It has been deemed capable of effecting clinically significant weight loss—that is if you don’t swallow it with a cola and dunk down a doughnut for good measure. This biopharmaceutical company that focuses on obesity has already seen its stock value on Nasdaq soaring by 80 per cent. Watch this space. We’re keeping tabs on Contrave.
Page 1 of 1